INSIGHTS-JOURNAL OF
LIFE AND SOCIAL SCIENCES

INSIGHTS-JLSS
Insights-Journal of Life and Social Sciences

EMERGING TRENDS IN THE MANAGEMENT OF GESTATIONAL DIABETES MELLITUS A NARRATIVE REVIEW

Narrative Review

Irfan Ishaque[1]*, Zunaira Naveed[2], Tahir Hafeez[3], Rimal Rashid[4], Esha Ali[5], Mahwish Ashraf[6]

[1]Department of Zoology, Government College University, Lahore, Pakistan.
[2]Woman Medical Officer, Gynaecology and Obstetrics Department, Gujranwala Medical College Teaching Hospital, Gujranwala, Pakistan.
[3]CEO & Founder, Tahir Holistic Healing & Research Institute, Mandi Bahauddin, Pakistan.
[4]Dow University Hospital, Karachi, Pakistan.
[5]Medical Student (4th Year), Riphah International University, Rawalpindi, Pakistan.
[6]Wah Medical College, Wah Cantt, Pakistan.

Corresponding Author: Irfan Ishaque, Department of Zoology, Government College University, Lahore, Pakistan, iamirfanishaque@gmail.com

Conflict of Interest: None

Grant Support & Financial Support: None

Acknowledgment: The authors acknowledge the valuable contributions of all researchers and clinicians whose work on gestational diabetes mellitus has informed this review. No specific funding was received for this study.

ABSTRACT

Background: Gestational diabetes mellitus (GDM) is one of the most prevalent metabolic complications in pregnancy, associated with significant short- and long-term risks for both mother and child. Rising maternal age, obesity, and sedentary lifestyles have contributed to its growing global burden. Timely and effective management of GDM is critical to improving perinatal outcomes and preventing future metabolic disease.

Objective: This narrative review aims to explore emerging trends in the management of GDM, including innovations in screening, dietary and pharmacological interventions, and the integration of digital tools into clinical practice.

Main Discussion Points: Recent literature emphasizes the shift toward individualized care approaches, incorporating tailored nutritional therapy and exercise as foundational treatment. Pharmacologic options have expanded to include insulin analogs and oral hypoglycemic agents such as metformin, though long-term safety data remain limited. Advances in digital health—particularly continuous glucose monitoring systems—offer enhanced glycemic tracking and patient engagement. However, inconsistencies in diagnostic criteria, outcome measurements, and follow-up practices limit the comparability of studies. Additionally, the generalizability of findings is constrained by population homogeneity and underrepresentation of low-resource settings.

Conclusion: Emerging strategies are reshaping the management of GDM toward more personalized, technology-integrated models. While evidence supports the effectiveness of several novel interventions, the current literature is marked by methodological limitations. Future research should prioritize large-scale, diverse, and longitudinal studies to inform standardized guidelines and equitable care delivery.

Keywords: Gestational Diabetes Mellitus, Pharmacologic Therapy, Nutritional Management, Digital Health, Pregnancy, Narrative Review.

INTRODUCTION

Gestational diabetes mellitus (GDM) is a growing public health concern, recognized as one of the most common metabolic disorders complicating pregnancy. Characterized by glucose intolerance first identified during gestation, GDM affects approximately 7–10% of pregnancies globally, although reported prevalence varies due to differences in screening strategies and diagnostic thresholds. The rise in maternal age, obesity, and sedentary lifestyles has contributed to an increasing burden of GDM, which poses significant risks for both maternal and neonatal health outcomes. These include heightened chances of hypertensive disorders, cesarean deliveries, macrosomia, neonatal hypoglycemia, and long-term metabolic complications for offspring (1,2). The medical and societal implications of GDM extend well beyond pregnancy. Women diagnosed with GDM face a substantially elevated risk of developing type 2 diabetes mellitus (T2DM) later in life, while their offspring may also demonstrate increased susceptibility to obesity and impaired glucose tolerance during childhood and adolescence (3,4). In light of these repercussions, early identification and timely intervention for GDM are essential in mitigating both immediate and future health risks. However, despite increasing awareness and clinical focus, consensus on best practices for diagnosis and management remains inconsistent across regions and institutions.

Current evidence highlights a variety of strategies aimed at managing GDM, with dietary therapy and lifestyle modifications forming the cornerstone of initial treatment approaches. Nutritional therapy combined with moderate physical activity has shown efficacy in maintaining euglycemia, with structured dietary plans often emphasizing low-glycemic foods and portion control (5). Nonetheless, in cases where glycemic targets remain unmet, pharmacological interventions become necessary. Traditionally, insulin therapy has been the standard of care, but newer evidence supports the use of oral hypoglycemic agents like metformin and glyburide, which may offer comparable efficacy with added convenience (6,7). Technological advances have also begun to reshape GDM management. The integration of continuous glucose monitoring systems (CGMS) and digital health platforms offers enhanced real-time glucose control, increased patient engagement, and improved adherence. These tools may prove particularly valuable in high-risk pregnancies requiring tighter glycemic monitoring or in populations with limited access to frequent in-person consultations. Furthermore, novel insulin analogs such as aspart, lispro, and detemir have shown superior pharmacokinetic profiles and reduced hypoglycemic risk compared to older formulations, providing additional flexibility in clinical care (8,9).

Despite the growing body of research, key knowledge gaps persist in several areas. The optimal screening time and criteria for GDM remain contentious, with ongoing debates regarding the use of one-step versus two-step diagnostic protocols. Additionally, more evidence is needed to assess the long-term safety and effectiveness of oral antidiabetic agents in diverse populations, especially in light of genetic and ethnic variations that may influence drug metabolism and disease presentation. Furthermore, the utility of emerging preventive strategies—such as the use of probiotics, vitamin D supplementation, and exercise interventions initiated in early pregnancy—requires further validation through large-scale randomized controlled trials (10-12). Given the rapid evolution in clinical understanding and technological innovation, this narrative review aims to explore emerging trends in the management of GDM. Specifically, it will examine advancements in screening protocols, dietary and pharmacological interventions, and the integration of digital tools in clinical practice. By synthesizing contemporary evidence and highlighting areas for future investigation, the review seeks to offer clinicians a comprehensive and practical guide to optimizing GDM management in modern healthcare settings. The significance of this review lies in its timely appraisal of both established and novel practices, thereby addressing the pressing need for unified, evidence-based guidance in GDM care. As healthcare systems globally strive to balance individualized patient care with scalable, cost-effective interventions, this review underscores the importance of integrating multidisciplinary strategies that prioritize maternal and fetal outcomes both during and beyond pregnancy.

THEMATIC DISCUSSION

Evolving Approaches to Screening and Diagnosis

Over the past decade, the approach to screening for gestational diabetes mellitus (GDM) has seen considerable refinement, driven by the need for early and accurate detection. While traditional diagnostic paradigms relied heavily on two-step testing strategies, including initial glucose challenge tests followed by oral glucose tolerance tests (OGTT), recent shifts favor the one-step 75g OGTT as recommended by the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) due to its increased sensitivity. However, controversy remains over the optimal approach. Some regions continue to prefer the two-step method for its lower cost and reduced burden on patients. The lack of a universally accepted standard leads to significant disparities in GDM prevalence worldwide,

with reported rates ranging from 1% to over 20% depending on the criteria applied (1,2). This variability complicates cross-study comparisons and poses a major challenge for global health policy harmonization.

Lifestyle Interventions: First-Line and Foundational Therapy

Nutritional management and physical activity are consistently identified as the first-line interventions for GDM. Medical nutrition therapy (MNT) aims to maintain euglycemia while supporting appropriate weight gain and fetal development. Recent studies emphasize individualized dietary planning with attention to cultural food preferences and patient education to ensure adherence (3). Physical activity, particularly moderate-intensity aerobic exercise, has also emerged as a critical adjunct to dietary therapy, with evidence suggesting a reduction in fasting glucose levels and improved insulin sensitivity (4). Despite consistent support for these measures, their implementation in clinical practice varies widely. Barriers include lack of patient engagement, resource limitations, and inconsistent provider recommendations.

Pharmacological Advancements in Glycemic Control

While lifestyle interventions remain central, up to 30% of women with GDM require pharmacological support. Insulin has long been the standard of care due to its established safety profile in pregnancy. However, emerging data support the increasing use of oral hypoglycemic agents, particularly metformin. Several studies report that metformin is effective in achieving glycemic targets and may offer additional benefits such as lower maternal weight gain and reduced neonatal adiposity (5,6). Insulin analogs such as detemir and aspart are also gaining favor due to their improved pharmacokinetics and reduced risk of hypoglycemia compared to human insulin (7). However, concerns persist regarding the long-term effects of in utero exposure to metformin, particularly with respect to childhood growth and metabolic outcomes. As a result, metformin is often reserved for cases where patients are unable or unwilling to use insulin, underscoring an ongoing area of debate.

Integration of Digital Tools in GDM Management

Technology-driven solutions are transforming the way GDM is managed. Digital health platforms and mobile applications offer glucose tracking, dietary logging, teleconsultations, and education modules, empowering women to manage their condition actively. Continuous glucose monitoring systems (CGMS) have shown promise in improving glycemic control and reducing the frequency of severe hypoglycemia (8). Moreover, these tools facilitate real-time clinician feedback and improve patient compliance. However, challenges such as cost, digital literacy, and equitable access limit their widespread adoption. Evidence supporting their effectiveness is still evolving, with some studies reporting minimal differences in outcomes compared to standard self-monitoring of blood glucose (SMBG), calling for further research.

Postpartum Follow-Up and Long-Term Implications

GDM is now widely recognized not just as a transient gestational condition but as a predictor of future metabolic dysfunction. Women with prior GDM have a sevenfold increased risk of developing type 2 diabetes within 5–10 years postpartum (9). Postpartum follow-up, however, is inconsistently implemented. A significant proportion of women fail to undergo recommended glucose testing within 6–12 weeks of delivery. Longitudinal studies emphasize the importance of structured follow-up, lifestyle counseling, and, where appropriate, pharmacological prevention using agents like metformin for women who develop prediabetes (10,11). Digital reminders and integration of postpartum care into routine maternal health services have shown potential in improving follow-up rates but require robust systems for scalability.

Maternal and Neonatal Outcomes

Effective GDM management is associated with reductions in macrosomia, shoulder dystocia, preeclampsia, and neonatal hypoglycemia. Evidence shows that strict glycemic control correlates with improved perinatal outcomes regardless of the method used to achieve it (12). However, overtreatment poses its risks, particularly through overly restrictive diets or aggressive insulin regimens, which can lead to small-for-gestational-age (SGA) infants. This balancing act highlights the importance of individualized treatment plans that adjust therapy based on maternal weight, glucose trends, and fetal growth metrics. Despite advances in treatment, disparities in maternal and neonatal outcomes persist among ethnic minorities, pointing to underlying systemic inequities that require targeted intervention.

Gaps and Controversies in Current Practice

Despite extensive research, several gaps persist. The optimal timing for initiating screening in high-risk populations remains unclear. Similarly, disagreement exists over the safety and long-term metabolic impact of oral agents, particularly in non-obese and early-diagnosed women. Moreover, limited data exist regarding the integration of culturally competent care into GDM management—an issue that disproportionately affects women from diverse ethnic backgrounds. The use of probiotics, vitamin D, and myoinositol as potential preventive agents has garnered interest but remains unsupported by large-scale randomized trials. Additionally, the long-term outcomes for children exposed to various management regimens in utero remain a subject of ongoing investigation.

Toward a Personalized, Multidisciplinary Model of Care

The future of GDM management lies in personalization—leveraging biomarkers, digital health, and patient-specific risk factors to tailor care. Multidisciplinary teams involving obstetricians, endocrinologists, dietitians, and behavioral health professionals have shown promise in improving adherence and outcomes. Integrating patient-centered approaches into routine antenatal care may bridge many existing gaps and improve both maternal and neonatal outcomes. Efforts must also focus on policy-level changes that prioritize postpartum care and preventative strategies beyond delivery.

CRITICAL ANALYSIS AND LIMITATIONS

The existing literature on the management of gestational diabetes mellitus (GDM) has significantly expanded in recent years, yet a critical evaluation reveals several methodological and interpretative limitations that restrict the robustness and applicability of findings. One of the foremost concerns lies in the heterogeneity of study designs, many of which rely on observational frameworks or retrospective analyses. While such studies provide valuable real-world insights, their inherent limitations, including lack of randomization and control groups, limit the strength of causal inferences. Randomized controlled trials (RCTs), which are the gold standard for evaluating clinical interventions, remain underrepresented in this domain. Even when RCTs are conducted, they often involve small sample sizes or focus on narrowly defined patient groups, thus reducing statistical power and increasing the risk of Type II errors (12). Another significant limitation pertains to short follow-up durations. Many studies assess outcomes limited to the antenatal or immediate postpartum period, thereby missing critical information about long-term maternal and neonatal metabolic health. For example, the enduring effects of intrauterine exposure to pharmacologic agents like metformin on offspring's weight trajectories or insulin sensitivity are not comprehensively examined in most trials, despite preliminary evidence suggesting long-term implications (13). This lack of longitudinal data constrains the capacity to develop informed clinical guidelines addressing postnatal and intergenerational risks associated with GDM.

Methodological bias is also prevalent across studies. Selection bias frequently arises from the recruitment of relatively homogeneous populations, often excluding women with comorbid conditions or those from low-resource settings. This selective sampling impairs the generalizability of findings to broader, more diverse populations. Additionally, performance bias—stemming from the lack of blinding in behavioral or pharmacological interventions—is a recurrent issue. In many trials comparing metformin and insulin, patients and clinicians are often aware of treatment allocation, which can inadvertently influence behavioral compliance or outcome reporting (14,15). Confounding factors, such as baseline body mass index, socioeconomic status, and parity, are not consistently adjusted for across studies, potentially distorting effect sizes. For instance, while exercise and dietary interventions are widely supported, the absence of standardized protocols and differing levels of patient adherence make it difficult to disentangle the intervention's true efficacy from external influences (16). These variations hinder accurate cross-study comparisons and can lead to misleading conclusions about the effectiveness of particular management strategies. Publication bias is another concern that cannot be overlooked. Positive findings, particularly those demonstrating significant improvements in glycemic control or neonatal outcomes, are more likely to be published, while negative or null results remain underreported. This selective visibility creates a skewed understanding of the relative benefits of newer pharmacological agents or digital tools, thereby reinforcing potentially inflated expectations of their efficacy. A systematic underrepresentation of studies with modest or inconclusive findings can thus distort meta-analyses and policy recommendations (17,18).

Inconsistencies in outcome measurement further complicate the interpretation of results. Different studies utilize varied endpoints to define treatment success—ranging from mean fasting glucose levels and postprandial targets to maternal weight gain, neonatal birth weight, and composite perinatal morbidity indices. Such variability limits the ability to synthesize data meaningfully and to generate universal benchmarks for clinical effectiveness. For example, while some studies prioritize neonatal macrosomia as a primary endpoint,

others focus solely on maternal glycemic metrics, potentially neglecting broader implications on fetal health (19). Generalizability remains a pressing challenge. Much of the research originates from high-income countries with well-resourced healthcare systems, limiting the extrapolation of findings to lower-income regions where access to insulin, digital monitoring, or multidisciplinary care teams is often constrained. Moreover, cultural, dietary, and genetic differences are rarely accounted for, despite their known influence on glucose metabolism and treatment responsiveness. This geographic and demographic limitation underscores the urgent need for inclusive, multicenter trials that incorporate ethnically and socioeconomically diverse cohorts (20). In sum, while the literature on GDM management has grown in scope and complexity, its utility in guiding universal clinical practice is curtailed by methodological inconsistencies, underrepresentation of rigorous trial designs, and lack of diverse participant populations. A more standardized and globally coordinated research agenda, supported by well-powered RCTs and long-term follow-up studies, is essential to bridge current gaps and strengthen the evidence base for personalized, equitable, and effective care.

IMPLICATIONS AND FUTURE DIRECTIONS

The findings from this narrative review offer significant implications for improving clinical practice in the management of gestational diabetes mellitus (GDM). As evidence continues to evolve, clinicians are better equipped to personalize treatment strategies, moving beyond one-size-fits-all models. For instance, integrating oral hypoglycemic agents such as metformin, in appropriate candidates, may provide a more patient-friendly alternative to insulin without compromising perinatal outcomes. This aligns with a shift towards less invasive, more acceptable treatment modalities for pregnant women, potentially improving adherence and satisfaction with care (21). Similarly, the use of digital tools and continuous glucose monitoring systems (CGMS) can enhance patient engagement and facilitate tighter glycemic control, particularly for those requiring intensive monitoring or living in remote areas (22). These tools, when incorporated thoughtfully, may reduce the frequency of hospital visits and allow for real-time therapeutic adjustments, ultimately promoting safer pregnancies. From a policy and guideline perspective, there is a pressing need to standardize screening and diagnostic protocols globally. The persistent variability in diagnostic criteria and screening approaches contributes to significant differences in reported prevalence and treatment thresholds. This inconsistency underscores the importance of developing universally accepted clinical guidelines that reflect the latest evidence while allowing adaptability for local resource availability and patient demographics (23). Policymakers must also consider incorporating postpartum surveillance for women with GDM into routine maternal care pathways. Given the high risk of progression to type 2 diabetes mellitus, structured follow-up programs that include lifestyle counseling, glycemic testing, and risk stratification tools should be institutionalized to reduce long-term health burdens on both mothers and their offspring (24).

Despite substantial advances, several unanswered questions remain. The long-term safety profile of pharmacologic agents like metformin on offspring metabolic health is not fully understood. While short-term outcomes appear reassuring, longitudinal studies assessing developmental and metabolic parameters into adolescence and adulthood are critically lacking. Furthermore, the comparative effectiveness of CGMS versus traditional self-monitoring blood glucose (SMBG) approaches in routine pregnancies—not just high-risk cases—requires additional investigation. There is also limited evidence on how digital platforms can be effectively scaled in low- and middle-income countries where access to technology and trained personnel is limited (25). To address these gaps, future research should prioritize well-designed, adequately powered randomized controlled trials with diverse populations. Such studies must include long-term follow-up periods extending into the postnatal years to capture the full trajectory of maternal and child health outcomes. Additionally, future trials should focus on standardizing outcome measures, such as definitions of treatment success and adverse events, to allow for better comparison and synthesis across studies. Multicenter and multinational trials will be especially valuable in enhancing the external validity of findings, considering the variation in dietary habits, genetic predispositions, and healthcare infrastructures worldwide (26). Adaptive trial designs, which allow for real-time modification of study protocols based on interim results, may also be beneficial in rapidly evolving areas such as digital health and personalized medicine. In summary, this review highlights actionable insights for improving clinical management, supports the call for harmonized global guidelines, and identifies specific avenues for future inquiry. A concerted effort from clinicians, researchers, and policymakers is needed to refine GDM care in ways that are evidence-based, patient-centered, and equitable across different healthcare settings.

CONCLUSION

This review highlights the evolving landscape in the management of gestational diabetes mellitus, underscoring significant advancements in screening protocols, dietary and pharmacologic interventions, and the growing utility of digital tools. While individualized nutritional therapy and physical activity remain the cornerstone of treatment, newer pharmacologic options like metformin and insulin analogs have broadened therapeutic choices, particularly for women with poor glycemic control. The integration of digital health technologies, such as continuous glucose monitoring systems, presents a promising avenue for enhancing patient engagement and clinical outcomes. Despite these developments, the current body of evidence varies in methodological rigor, with many studies limited by small sample sizes, inconsistent outcome measures, and lack of long-term follow-up. Clinicians should prioritize personalized, culturally sensitive approaches, ensure postpartum follow-up, and advocate for multidisciplinary care models. To solidify best practices, future research must emphasize large-scale, multiethnic randomized controlled trials with standardized methodologies and extended follow-up periods to assess both maternal and offspring outcomes. A cohesive global research agenda and consistent clinical guidelines are essential to address existing gaps and optimize care for women with gestational diabetes across diverse healthcare settings.

AUTHOR CONTRIBUTION

Author	Contribution
Irfan Ishaque*	Substantial Contribution to study design, analysis, acquisition of Data Manuscript Writing Has given Final Approval of the version to be published
Zunaira Naveed	Substantial Contribution to study design, acquisition and interpretation of Data Critical Review and Manuscript Writing Has given Final Approval of the version to be published
Tahir Hafeez	Substantial Contribution to acquisition and interpretation of Data Has given Final Approval of the version to be published
Rimal Rashid	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Esha Ali	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Mahwish Ashraf	Substantial Contribution to study design and Data Analysis Has given Final Approval of the version to be published

REFERENCES

1. Léniz A, González M, Besné I, Carr-Ugarte H, Gómez-García I, Portillo MP. Role of chemerin in the control of glucose homeostasis. Mol Cell Endocrinol. 2022;541:111504.
2. Kusinski LC, Jones D, Atta N, Turner E, Smith S, Oude Griep LM, et al. Reduced-energy diet in women with gestational diabetes: the dietary intervention in gestational diabetes DiGest randomized clinical trial. Nat Med. 2025;31(2):514-23.
3. Hernandez TL, Farabi SS, Fosdick BK, Hirsch N, Dunn EZ, Rolloff K, et al. Randomization to a Provided Higher-Complex-Carbohydrate Versus Conventional Diet in Gestational Diabetes Mellitus Results in Similar Newborn Adiposity. Diabetes Care. 2023;46(11):1931-40.
4. Laredo-Aguilera JA, Gallardo-Bravo M, Rabanales-Sotos JA, Cobo-Cuenca AI, Carmona-Torres JM. Physical Activity Programs during Pregnancy Are Effective for the Control of Gestational Diabetes Mellitus. Int J Environ Res Public Health. 2020;17(17).
5. Kasuga Y, Takahashi M, Kajikawa K, Akita K, Otani T, Ikenoue S, et al. Perinatal Outcomes of Diet Therapy in Gestational Diabetes Mellitus Diagnosed before 24 Gestational Weeks. Nutrients. 2024;16(11).
6. Rademaker D, de Wit L, Duijnhoven RG, Voormolen DN, Mol BW, Franx A, et al. Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial. Jama. 2025;333(6):470-8.

7. Berti GN, Garcia IGO, de Toledo J, Tatemoto JR, Marino LW, Legori MM, et al. Metformin versus insulin in gestational diabetes mellitus: a systematic review. Rev Bras Ginecol Obstet. 2024;46.
8. Pourkarim F, Entezari-Maleki T. Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Pregnancy. Jama. 2024;331(17):1502.
9. Petrie JR. Metformin beyond type 2 diabetes: Emerging and potential new indications. Diabetes Obes Metab. 2024;26 Suppl 3:31-41.
10. Benhalima K, Beunen K, Siegelaar SE, Painter R, Murphy HR, Feig DS, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol. 2023;11(7):490-508.
11. Pérez-Pérez A, Vilariño-García T, Guadix P, Dueñas JL, Sánchez-Margalet V. Leptin and Nutrition in Gestational Diabetes. Nutrients. 2020;12(7).
12. Chen X, Chen H, Wei F, Chen K. Global Research Trends in Gestational Diabetes Mellitus from 2000 to 2020: A Bibliometric Study. Zeitschrift fur Geburtshilfe und Neonatologie. 2022.
13. Hakimi M, Subarto C, Isnaeni Y. Gestational diabetes mellitus: management during and after pregnancy - a systematic literature review. 2020;3:63-72.
14. Pigato F, Candido R, Zanette G, Zamagni G, Trojniak MP, Brunato B, et al. Gestational diabetes mellitus: Impact of adherence on patient management and maternal-neonatal complications. Prim Care Diabetes. 2023;17(5):486-92.
15. Seely E, Zera C. Gestational Diabetes Mellitus. DeckerMed Medicine. 2020.
16. Xie Y, Zhao H, Zhao M, Huang H, Liu C, Huang F, et al. Effects of resistance exercise on blood glucose level and pregnancy outcome in patients with gestational diabetes mellitus: a randomized controlled trial. BMJ Open Diabetes Res Care. 2022;10(2).
17. Huifen Z, Yaping X, Meijing Z, Huibin H, Chunhong L, Fengfeng H, et al. Effects of moderate-intensity resistance exercise on blood glucose and pregnancy outcome in patients with gestational diabetes mellitus: A randomized controlled trial. J Diabetes Complications. 2022;36(5):108186.
18. Paulsen CP, Bandak E, Edemann-Callesen H, Juhl CB, Händel MN. The Effects of Exercise during Pregnancy on Gestational Diabetes Mellitus, Preeclampsia, and Spontaneous Abortion among Healthy Women-A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2023;20(12).
19. Zhang L, Wang F, Tashiro S, Liu PJ. Effects of Dietary Approaches and Exercise Interventions on Gestational Diabetes Mellitus: A Systematic Review and Bayesian Network Meta-analysis. Adv Nutr. 2024;15(12):100330.
20. Rasmussen L, Poulsen CW, Kampmann U, Smedegaard SB, Ovesen PG, Fuglsang J. Diet and Healthy Lifestyle in the Management of Gestational Diabetes Mellitus. Nutrients. 2020;12(10).
21. Rademaker D, van der Wel AWT, van Eekelen R, Voormolen DN, de Valk HW, Evers IM, et al. Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial. Diabetes Obes Metab. 2023;25(12):3798-806.
22. Xu H, Liu R. Comprehensive management of gestational diabetes mellitus: practical efficacy of exercise therapy and sustained intervention strategies. Front Endocrinol (Lausanne). 2024;15:1347754.
23. Yang X, Han R, Xiang Z, Li H, Zhao Q, Chen L, et al. Clinical practice guidelines on physical activity and exercise for pregnant women with gestational diabetes mellitus: A systematic review. Int J Nurs Pract. 2023;29(6):e13141.
24. Xu J, Wang H, Bian J, Xu M, Jiang N, Luo W, et al. Association between the Maternal Mediterranean Diet and Perinatal Outcomes: A Systematic Review and Meta-Analysis. Adv Nutr. 2024;15(2):100159.
25. Keating N, Coveney C, McAuliffe FM, Higgins MF. Aerobic or Resistance Exercise for Improved Glycaemic Control and Pregnancy Outcomes in Women with Gestational Diabetes Mellitus: A Systematic Review. Int J Environ Res Public Health. 2022;19(17).
26. Kanawade S, Vikhe C, Patare V, Pawar H. Advances in Understanding and Managing Gestational Diabetes Mellitus: A Comprehensive Review. Research Journal of Pharmacology and Pharmacodynamics. 2024.

